Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...
CPC review of 5,000 sales finds Compass at 29.7% to 39.5% share in five metros, raising double-ending and private listing ...
Space Compass and SWISSto12 have executed a procurement contract for the first GEO optical data relay satellite. This agreement represents a milestone toward the realisation of Space Compass’s optical ...
Compass, Zillow, and eXp rolled out coming soon programs with different rules on exclusivity, MLS limits and lead routing.
Magnetic rocks with iron oxide concentrations act as natural chroniclers of Earth's past continental movements. Using small ...
(From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering ...
Investing.com - Stifel reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ:CMPX) shares, well above the current stock price of $5.10. The biotech company has delivered a ...
Before downloading the whitepaper, we would like to ask you to complete your profile with company and position. After confirming you will receive the white paper.
Access detailed historical stock prices, including daily closing prices, for COMP. Analyze past performance trends, track price movements, and explore historical data to inform your investment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results